Search results for "Hepatitis C"
Did you mean "hepatitis"?
Sort by: Relevance | Newest | OldestReformulation of extended-release oxycodone may have triggered increase in hepatitis C rates
Hepatitis C virus infections increased three times faster in states with above-median rates of initial misuse of extended-release oxycodone (OxyContin) than in states with below-median rates, and the increase began immediately after a reformulation of the drug in 2010.
https://gastroenterology.acponline.org/archives/2019/02/22/1.htm
22 Feb 2019
ID, liver societies update guidance for HCV testing, management
Major changes to guidance on hepatitis C virus (HCV) include an emphasis on universal screening, new recommendations for managing incomplete treatment adherence, and expansion of treatment eligibility, among others.
https://gastroenterology.acponline.org/archives/2023/06/23/6.htm
23 Jun 2023
8 weeks of ledipasvir/sofosbuvir may be effective for genotype 1 hepatitis C
The therapy should be considered in patients with genotype 1 infection who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load below 6,000,000 IU/mL, a study found.
https://gastroenterology.acponline.org/archives/2017/03/24/2.htm
24 Mar 2017
MKSAP Quiz: Hepatocellular carcinoma surveillance after HCV treatment
This month's quiz asks readers to determine the most appropriate biannual surveillance modality for a 62-year-old patient with compensated cirrhosis who was treated for hepatitis C virus (HCV) infection six months ago.
https://gastroenterology.acponline.org/archives/2021/10/22/4.htm
22 Oct 2021
HCV treatment effective, but underutilized, studies show
One study found that re-infection rates are low after successful hepatitis C virus (HCV) treatment in people who inject drugs, while another found that use of direct-acting antivirals in patients diagnosed with HCV is low, regardless of insurance status.
https://gastroenterology.acponline.org/archives/2022/08/26/3.htm
26 Aug 2022
HCV medications decreased liver disease among those using injection drugs
A Baltimore-based study found that half of participants with chronic hepatitis C virus (HCV) and a history of injection drug use at baseline were free of the virus by 2019, with associated reductions in their risk of cirrhosis and mortality.
https://gastroenterology.acponline.org/archives/2022/07/22/2.htm
22 Jul 2022
Spotlight on improving HCV care
A systematic review and meta-analysis assessed which interventions may improve hepatitis C virus (HCV) testing, linkage to care, and treatment initiation, while a randomized trial found that an accessible care model may be superior to facilitated referral at curing HCV in individuals who inject drugs.
https://gastroenterology.acponline.org/archives/2022/03/25/5.htm
25 Mar 2022
Patients had high adherence to HCV treatment delivered in opioid agonist therapy programs
The hepatitis C virus (HCV) treatment completion rate was 97% among all participants, including those actively using drugs.
https://gastroenterology.acponline.org/archives/2019/04/26/6.htm
26 Apr 2019
Spotlight on direct-acting antivirals
Studies of contemporary populations with hepatitis C virus infection demonstrated that treatment with direct-acting antiviral therapies was linked to improvement in several long-term clinical outcomes.
https://gastroenterology.acponline.org/archives/2019/02/22/5.htm
22 Feb 2019
High HCV cure rate seen with FDA-approved direct-acting antiviral regimens
Six of the direct-acting antiviral (DAA) regimens yielded sustained virologic response rates above 95% in patients who had hepatitis C virus (HCV) genotype 1 without cirrhosis, including those with HIV co-infection.
https://gastroenterology.acponline.org/archives/2017/03/24/7.htm
24 Mar 2017